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Abstract 
The pathological processes leading to heart failure are characterised by the 
formation of fibrosis and scar, yet the dynamics of scar production and removal are 
incompletely understood. Spontaneous disappearance of myocardial collagen is reported in 
infancy but doubted in adulthood where scar volume constitutes a better prognostic 
indicator than the conventional parameters of ventricular function. Whilst certain drugs are 
known to attenuate myocardial fibrosis evidence is emerging that stem cell therapy also has 
the potential to reduce scar size and improve myocardial viability. Both animal studies and 
clinical trials support the concept that, as in infancy, cellular processes can be triggered to 
remove collagen and regenerate injured myocardium. The molecular mechanisms likely 
involve anti-fibrotic cytokines growth factors and matrix-metalloproteinases. Autologous 
cardiac, bone-marrow and adipose tissue derived stem cells have each shown efficacy. 
Specific immune privileged mesenchymal stem cells and genetically modified 
immunomodulatory progenitor cells may in turn provide an allogenic source for the 
paracrine effects. Thus autologous and allogenic cells both have the potential through 
paracrine action to reduce scar volume, boost angiogenesis and improve ventricular 
morphology. The potential benefit of myocardial cell therapy for routine treatment of heart 
failure is an area that requires further study. 
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Introduction 
Surgery for anomalous left coronary artery from the pulmonary artery (ALCAPA} 
provides a rare opportunity to explore the potential for cardiac regeneration in the very 
young1. These children present with myocardial infarction in infancy. Excision of myocardium 
in a reported case showed a mix of partial thickness scar and diffuse fibrosis; twelve years on 
magnetic resonance imaging showed the ventricle to look virtually normal, with all scar and 
fibrosis gone 2• Others have shown resolution of scar in adolescents after ALCAPA surgery3• 
How does the scar and fibrosis disappear? It appears that endogenous cardiac stem cells 
remain active for a finite time in infant and childhood myocardium and serve to reverse 
remodel the scarred ventricle. So, in the era of regeneration therapy could the same process 
be engineered for adult patients? 
Development of cardiac fibrosis 
Fibroblasts have a prominent role in the development of cardiac fibrosis. Their multilineage 
origin and their potential regulatory interactions are incompletely understood. Fibroblasts 
are distributed throughout the normal myocardium as strands and sheets between cardiac 
muscle fibres and are responsible cardiac structural and functional homeostasis. They express 
paracrine and cytokines and have complex interaction with cardiomyocytes, influencing their 
development and growth, and how they may adapt to physiological and pathophysiological 
circumstances4· 7. Fibroblasts are responsible for the formation and maintenance of cardiac 
connective tissue, which have cellular and acellular components5• 8 that provide a scaffold for 
cardiomyocytes and for the whole heart9. The acellular component of the cardiac connective 
tissue is referred to as the extracellular matrix (ECM). Fibroblasts have the potential to 
migrate to areas of myocardium that have been damaged, for example during acute 
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myocardial infarction, pressure and volume overload states. Fibroblasts intereact with pro-
inflammatory cellular and signalling pathways, that lead to fibroblasts trans-differentiation 
into myofibroblasts, which are the primary effector cells in cardiac remodelling and fibrosis 
as summarised in figure 1. Myofibroblast do not appear in the normal myocardium, they may 
also originate from trans-differentiation of various other cell types such as fibrocyte, epithelial 
and epicardial, endothelial and haematopoietic cells into fibroblasts before they become 
activated into myofibroblasts10-13. The process of myofibroblast activation many mechanisms 
such as signaling from cytokines such as transforming growth factor (TGF-~), platelet-derived 
growth factor (PDGF), connective-tissue growth factor (CCN2), WNT-p-catenin, endothelin 1 
(ET-1) and angiotensin 115• 14• Neutrophils may also contribute to myofibroblast activation by 
means of NETosis, in which the enzyme peptidyl arginine deiminase type IV (PADl4) 
citrullinates arginine residues in histone tails within neucleosomes of neutrophils, leading to 
the release of decondensed chromatin concomitant with the activation of neutrophil- platelet 
complexes15 . Pro-inflammatory cellular and fibrotic signalling pathways include TNF-a. and 
IL-lp, aldosterone, angiotensin II, endothelin-1 and TGF-p, can lead to the apoptosis of 
cardiomyocytes, and via increased activity of matrix metalloproteinases and reduced activity 
of tissue inhibitor of matrix metalloproteinases (TIMPs) lead to breakdown of ECM, and 
adverse remodelling characterised by deposition of proteins such as precursors to collagen 
type I and type Ill 16• 17 by myofibroblasts within the ECM and formation of mature fibril-
forming collagen molecules that are organized into fibrils leading to myocardial fibrosis4• s, 
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• 
18 in the injured myocardium (i.e. reparative or replacement fibrosis), see figure 2, and also 
non-injured myocardium (i.e. reactive fibrosis). Cardiac fibrosis helps to preserve the integrity 
of the diseased heart; However, the consequences are increasing stiffness of the myocardial 
wall, impaired systolic and diastolic mechanical function and subsequent heart failure. 
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Although the aetiology and pattern of fibrosis is different, the pathological pathway to 
formation of fibrosis in ischemic (characterized by focal areas of fibrosis), idiopathic dilated 
and hypertrophic cardiomyopathies (characterized by diffuse fibrosis) is likely to be similar19-
21. Focal and diffuse fibrosis are associated with the development of electrophysiological 
abnormalities predisposing to cardiac arrhythmias22• Therefore, inhibiting or reversing 
fibrosis and its adverse consequences is an established target of many widely used clinical 
interventions for treating heart disease. Notably these have included drugs such as 
angiotensin-converting enzyme (ACE) inhibitors and aldosterone antagonist that in clinical 
studies have led to partial recovery of contractile function termed as 'reverse remodelling' 
which is associated better outcomes in heart failure 23• 24 • 
The Potential for Myocardial Regeneration in Adults 
In the absence of a powerful extrinsic stimulus the capacity for adult myocardium to 
regenerate itself is negligible. Yet in other parts of the animal kingdom that regenerative 
capacity appears to exist. Zebra fish , when the apex of its heart is excised are capable of 
regenerating new cardiomyocytes within 4 weeks25• Amir and colleagues showed that in 
biopsies taken from the right ventricle of neonates undergoing repair of congenital defects, 
the neonatal myocardium contains progenitor cells and transitional cells26 . They also found 
that the relative density of progenitor cells declines during the first postnatal month. 
Suggesting that natural repair systems may exist in the myocardium and could be 
therapeutically reactivated . Experience with anomalous left coronary artery from the 
pulmonary artery strongly supports this hypothesis2• 3 . The potential for the cardiomyocyte 
cell proliferation is indirectly supported by two recent clinical studies. Canseco et al 
demonstrated that prolonged mechanical unloading in patients with cardiomyopathy treated 
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by the use of left ventricular assist devices may induce adult human cardiomyocyte 
proliferation, possibly through prevention of mitochondria-mediated activation of DNA 
damage response27• The latter is an important mechanism of cell cycle arrest in postnatal 
mammalian cardiomyocytes28• In another clinical study, intravenous infusion of recombinant 
neuregulin, cimaglermin alfa {Neuregulin 1~3), a growth factor acting directly on 
cardiomyocytes and associated with cardiomyocyte proliferation, lead to a dose-dependent 
improvement in left ventricular ejection fraction in patients with heart failure and reduced 
ejection fraction already on optimal guideline-directed medical therapy29• Further studies are 
required to improve our understanding of the mechanism behind cardiomyocyte proliferation 
and thus potential of myocardial regeneration. 
Cell therapy 
Cell therapy has the potential to remove scar and improve cardiac function in disease states 
such as heart failure and post myocardial infarction. The exact mechanisms of cardiac repair 
by such cell therapy is unclear, and there are two hypothetical mechanism that have been 
considered. These include direct cardiomyocyte differentiation and indirect stimulation of the 
reparative responses by paracrine effects30• The origin, type and mode of delivery of stem 
cells is summarised in figure 3. In this review we have selected several clinical studies showing 
that cell therapy may reduce scar. These studies are categorised based on being autologous 
or allogenic stem cell or engineered lmmunomodulatory progenitor cell studies and are 
summarised in table 1. 
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Autologous Stem Cells and Scar Reduction 
Autologous stem cell therapy, refers to the administration of the subject's own stem 
cell, these may be isolated from endomyocardial tissue, subcutaneous adipose tissue or bone 
marrow, then prepared in vitro and then administered into the subject's own myocardium. 
Several studies discussed below have suggested that this method of cell therapy may reduce 
scar. 
Cardiac derived autologous stem cell: 
The Stem Cell Infusion in Patients with lschaemic Cardiomyopathy (SCIPIO) trial, 
patients with post-infarction left ventricular dysfunction (LVEF<40%) were enrolled into 
treatment and control groups before coronary artery bypass grafting31. During coronary 
artery bypass grafting the right atrial appendage was removed then c-kit-positive, lineage-
negative cardiac stem cells harvested, isolated and expanded at another hospital. The cells 
were re-administered by intra-coronary injection into the infarct related coronary on average 
130 days post operatively. Subjects receiving the stem cells have a significantly greater 
improvement in LVEF (30% to 38.5%) by 4 months and infarct size had decreased by 30% at 
one year after treatment as measured by MRI scan. Furthermore, the treated patients derived 
clinical benefit through increased functional capacity and improved quality of life. The results 
of this trial have been questioned following recent data in a mouse model that C-kit positive 
cells can lead to the generation of cardiomyocytes, however at low level which is insignificant 
to have an impact on cardiac function32, therefore not supporting the hypothesis of SCIPIO 
trial. 
In the Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular 
Dysfunction (CADUCEUS) trial, autologous cardiospheres were grown from endomyocardial 
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biopsies in patients who had suffered previous myocardial infarction33• The cells were given 
as an intra-coronary infusion in the infarct related artery in 17 patients with moderately 
reduced ejection fraction, on average 36 days after biopsy and 65 days post infarction. The 
absolute decrease in scar size was 45% for treated patients versus no change in controls one 
year after infusion. This translated into a sizeable decrease in scar mass and an increase in 
viable myocardium and systolic thickening. 
Adipose tissue derived autologous stem cells: 
Subcutaneous fat is a source of stem cells which can be readily obtained by 
liposuction, then prepared for immediate autologous transplantation without the need for 
culture or expansion34• These stem cells can differentiate into cardiomyocytes or endothelial 




• In the APOLLO 
prospective randomised double blind placebo controlled trial 14 patients with ST segment 
elevation myocardial infarction were given adipose derived cells or placebo via the 
intracoronary route then followed at six months with magnetic resonance imaging and single-
photon emission computed tomography37. Those who received cells had smaller scar size and 
better regional perfusion than controls. Similar results were also seen the in the PRECISE trial, 
in which the cells were delivered by trans-catheter endocardial injection34• 
Bone marrow derived autologous stem cell therapy: 
Mesenchymal stem cells have been tested in clinical trials in both acute myocardial 
infarction and ischaemic cardiomyopathy patients undergoing coronary artery bypass 
surgery. One of the first trials in myocardial infarction by Janssens et al suggested the ability 
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to reduce scar size38. The prospective Randomised Study of Mesenchymal Stem Cell Therapy 
in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial employed detailed segmental 
magnetic resonance imaging studies of treated areas of myocardium 39. Imaging suggested 
that mesenchymal stem cells exerted their effects locally at the site of injection contributing 
to reduced infarct size, enhanced tissue perfusion and improved segmental function. Whilst 
there did not appear to be an important effect on remote areas, scar mass was reduced by 
4 7.5% compared to baseline in the injected territory. 
The exact mechanism by which stem cell decrease scar mass is unclear, but it is likely 
to be via a paracrine fibrolytic mechanism. Then increase viable myocardium by recruitment 
of endogenous progenitors and induction of resident cardiomyocyte proliferation at the 
infarct border zone31• 33. These growth factor-based mechanisms depend upon activation of 
endogenous reparative and regenerative pathways rather than long term engraftment and 
differentiation of newly introduced stem cells . 
The harvesting of autologous cells from a sick patient poses logistic, economic and 
time constraints. Also, the majority of patients who could benefit from regenerative therapy 
are elderly with multiple comorbidities. A number of studies indicate that cells harvested 
from older donors with diabetes, renal failure or ischaemic heart disease manifest 
significantly reduced capacity for proliferation and neovascularization, limiting their 
therapeutic potentia 140. 
Allogenic Cell based Studies and scar reduction 
The ultimate goal is to identify a ubiquitous 'off the shelf' donor cell with high 
regenerative capacity for unrelated recipients. As the adult bone marrow stem cells, also 
known as mesenchymal stem cells, are immune-privileged, they are able to survive and 
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differentiate in immune-compatibility-mismatched allogenic or even xenogeneic recipients
41
. 
They are major histocompatibility class II negative but class I positive, thus protecting them 
from natural killer cell mediated elimination42• As a result, mesenchymal stem cells escape 
recognition by effector CD4+ T cells and avoid an allogenic rejection response43 • The signalling 
molecules secreted by mesenchymal stem cells are predominantly anti-inflammatory 
cytokines41. Laboratory studies have shown that mesenchymal stem cells reduce myocardial 
fibrosis and inhibit adverse remodelling through altered mRNA and protein expression of 





The TRIDENT (Transendocardial Stem cell injection delivery Effects on Neomyogenesis) study 
showed that in 30 patients with heart failure randomised to transendocardial injection of 20 
million (M) versus 100 M allogenic human mesenchymal stem cells. At 12 months, the group 
receiving 100 M cells had a reduction in scar size as well as an improving ejection fraction as 
measured by contrast CT46. Serum levels of TNF-a. were reduced in the study supporting the 
idea that mesenchymal cells may exert their benefits via an anti-inflammatory effect. A larger 
phase Ill study is being planned. 
Allogenic Engineered lmmunomodulatory Progenitor Cells and scar reduction 
Recently there has been research into the production of a "cardiac specific 
mesenchymal stem cell-like" allogenic cell specifically for clinical use
47
. The resulting 
immunomodulatory mesenchymal precursor cell type expresses significant upregulation of 
the markers CD 181, CD 182 and CD 304 as compared to conventional cells. These markers 
play an important role in the migration, penetration and angiogenic potential of stem cells. 
As such these immunomodulatory mesenchymal precursor cells are regarded as a "novel cell 
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type" by the International Society for Stem Cell Research48• They have been tested in an 
uncontrolled Phase II safety and efficacy trial where the cells were injected into the peri-
infarct zone of 11 ischemic cardiomyopathy patients undergoing coronary bypass surgery 
specifically targeting scarred segments which were not amenable to revascularisation 47. In 
this uncontrolled study there was a significant decrease in infarct size at one year with a mean 
percentile reduction in scar area of 42 .6%. Despite a lack of control, more than half of the 
patients also showed improved myocardial perfusion in territories designated "nonviable" 
before cell injection. The increased segmental perfusion correlated well with similar findings 
in the PROMETHEUS "injection only" segments which the authors compared with "surgically 
revascularised only" segments39 . Whilst the incomplete myocardial revascularisation 
undoubtedly contributed to an overall improvement in left ventricular ejection fraction and 
New York Heart Association functional class, coronary bypass grafts cannot remove scar. The 
mechanism for scar remova l is likely to be through paracrine effects of the injected cells, 
which promote degradation of collagen Type I. Further controlled studies are required to 
assess the efficacy of these allogenic cells. 
Conclusions 
Our improved understanding of fibroblast and myofibroblast function, although 
incomplete, and their complex interaction between cellular and signalling pathways that lead 
to cardiac fibrosis and subsequent impairment of myocardial function has led to the general 
agreement that the mechanisms behind sca r size reduction are multifactorial and paracrine 
in nature. Ce ll therapy may promote angiogenesis, removal of scar and possibly the renewa l 
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of function in nonviable myocardium; changes which could translate into functional benefit. 
However, this area requires further studies before cardiologists and cardiac surgeons can 
embrace regenerative medicine as an adjunct to their clinical endeavours. 
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Table 1 Human Clinical trials which demonstrated reduced myocardial scar size following 
cell therapy 
Trial Cell Cell Patients n Main Effects ref 
Origin Type no: 
Autologous Stem cell 
Reduced scar size 
SCIPIO 20 11 Heart c-kit+ lsc. CM 16 Improved LY function 31 
CADUCEUS 2014 Heart CDC Recent M l 25 Reduced scar size 33 
Reduced scar size 
APOLLO 2012 Adipose MSCs AMI 13 Improved segmental perfusion 37 
Reduced scar size 
PRECISE 20 14 Adipose MSCs lsc. CM 27 Improved oxygen consumption 34 
Bone Reduced scar size 
Janssens et al 2006 marrow MSCs AMI 67 Improved L V function 38 
Bone lsc. CM Reduced scar size 
PROMETHEUS 2014 Marrow MS Cs with CABG 6 Improved segmental perfusion 39 
and L V function 
Allogenic Stem cells 
TRIDENT Study 20 17 Bone MSC IScCM 30 Reduced scar 46 
Marrow lmprO\ed Ejection fraction 
Allogenic lmmunomodulatory engineered progenitor cells 
Bone l sc. CM Reduced scar size 
Anastasiadis et al 20 16 Marrow iMPs with CABG II Improved L V function 47 
MSCs - mesenchymal stem cells, c-kit+ cardiospheres, CDC - cardiac derived stem cells 
iMPs - immunomodulatory progenitor cells, Auto - autologous, Al lo - allogenic. lSc.CM ischaemic cardiomyopathy, AM I -
acute myocardial infarction, Recent M 1 - recent myocardial infarction, LY - left ventricle 
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Potential cellular and molecular mechanism leading to formation of cardiac fibrosis. 
Myocardial Injury such as acute myocardial infarction leads to triggering of cellular and 
molecular mechanisms that lead to the development and activation of myofibroblasts, 
which are the primary effector cells that are central to development of excessive collagen 
deposition in the extracellular matrix required for repairing the injured myocardium and 
maintaining integrity of the heart. The subsequent cardiac fibrosis contributes to impaired 
systolic and diastolic function. Cellular and molecular pathways include secretion of 
cytokines (TGF-p, CCN2, PDGF, ET-1, angiotensin II} by macrophages, monocytes, 
lymphocytes and mast cell that lead to fibroblast trans-differentiation and activation into 
myofibroblasts. The latter also originate via trans-differentiation from other various cell 
types such as fibrocyte and peri-vascular and endothelial cells . Another important 
mechanism that leads to myofibroblast activation is by the process of NETosis, in which the 
enzyme peptidyl arginine deiminase type IV (PADl4) leads to the release of decondensed 
chromatin concomitant with the activation of neutrophil-platelet complexes (References 5 
to 12). At the same time the upregulation of MMPs and downregulation of TIMPS leads to 
degradation of the extracellular matrix. Myofibroblasts via pro-fibrotic signalling leads to 
collagen deposition in the extracellular matrix and subsequent cardiac fibrosis. 
Abbreviations: transforming growth factor~ (TGF-~), platelet-derived growth factor (PDGF), 
connective-tissue growth factor (CCN2), endothelin 1 (ET-1), matrix metalloproteinases 
(MMP), tissue inhibitor of metalloproteinases (TIMPs) and Extracellular matrix (ECM). 
(References 4 to 18) 
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Figure 2 
Cardiovascular Magnetic Resonance Imaging of scar 
Gadolinium-enhanced contrast cardiovascular magnetic resonance images of scar (also 
referred to as replacement fibrosis) representing full thickness myocardial infarction of the 
basal to mid inferior and lateral wall in short axis (a) and in 2 chamber (b) views. 
Figure 3 
Summary of origin, type and delivery of cells used in human stem cell studies 
Cardiosphere stem cells and c-Kit positive cell originate from cardiac tissue. Mesenchyma l 
stem cells may originate from bone marrow or adipose tissue. lmmunomodulatory 
progenitor cells, which are engineered from bone marrow of healthy individuals. Stem cells 
may be delivered via intra-myocardial injection via the epicardium at the time of cardiac 
surgery or by trans-catheter endocardial injection . Furthermore, cells may be delivered via 
coronary artery injection or via the cardiac vein. The patient's own stem cells may be 
isolated, prepared and then injected into the patient i.e. autologous or stem cells may be 
isolated from healthy humans, prepared and then injected into a patient i.e. allogenic. See 
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